brensocatib bronchiectasis investigational
Selected indexed studies
- Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults. (Clin Pharmacol Drug Dev, 2022) [PMID:35411669]
- Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. (ERJ Open Res, 2024) [PMID:39040578]
- Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis. (Clin Pharmacokinet, 2022) [PMID:35976570]
_Worker-drafted node — pending editorial review._
Connections
brensocatib bronchiectasis investigational is a side effect of
Sources
- Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults. (2022) pubmed
- Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. (2024) pubmed
- Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis. (2022) pubmed